EBMT 2024 | Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox, MbChB, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses an individualized approach to assessing potential risks of bone marrow transplantation in the treatment of primary immunodeficiency disorders (PIDs; or inborn errors of immunity). The combination of the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT CI) and the Immune Deficiency and Dysregulation Activity (IDDA) score allows for the individualization of transplant risk to guide treatment decisions. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
